S-Space

Browse

Author

Showing results 1 to 3 of 3

Issue Date	Title / Author(s) / Citation	File
2016-10	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity Ballard, Peter; Yates, James W. T.; Yang, Zhenfan; Kim, Dong-Wan; Yang, James Chih-Hsin; Cantarini, Mireille; Pickup, Kathryn; Jordan, Angela; Hickey, Mike; Grist, Matthew; Box, Matthew; Johnstrom, Peter; Varnas, Katarina; Malmquist, Jonas; Thress, Kenneth S.; Janne, Pasi A.; Cross, Darren Clinical Cancer Research, Vol.22 No.20, pp.5130-5140	DOI
2016-12	AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases Yang, Zhenfan; Guo, Qiuli; Wang, Yingchun; Chen, Kan; Zhang, Lin; Cheng, Ziqiang; Xu, Yanping; Yin, Xiaolu; Bai, Yu; Rabbie, Sarit; Kim, Dong-Wan; Ahn, Myung-Ju; Yang, James Chih-Hsin; Zhang, Xiaolin Science Translational Medicine, Vol.8 No.368, p. 368ra172	DOI
2017-11	Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study Ahn, Myung-Ju; Kim, Dong-Wan; Cho, Byoung Chul; Kim, Sang-We; Lee, Jong Seok; Ahn, Jin-Seok; Kim, Tae Min; Lin, Chia-Chi; Kim, Hye Ryun; John, Thomas; Kao, Steven; Goldman, Jonathan W.; Su, Wu-Chou; Natale, Ronald; Rabbie, Sarit; Harrop, Bryony; Overend, Philip; Yang, Zhenfan; Yang, James Chih-Hsin The Lancet Respiratory Medicine, Vol.5 No.11, pp.891-902	DOI